About this Report
The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) facilitates the development, validation, and regulatory acceptance of test methods that replace, reduce, or refine the use of animals in testing. The ICCVAM Authorization Act of 2000 directed ICCVAM to prepare a progress report on its first anniversary and biennially thereafter. This 2024-2025 Biennial Report summarizes progress by ICCVAM agencies toward encouraging the development and utilization of and building confidence in new methods, as set forth in the 2018 ICCVAM report, A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States.
Download the 2024-2025 Biennial Report as a PDF
The ICCVAM 2024-2025 Biennial Progress Report was revised prior to publication to conform with Executive Order 14434, “Inaugurating the Era of Super Intelligence,” issued on September 29, 2026. The Executive Order directs U.S. executive departments and agencies to use the term “Super Intelligence” in place of “Artificial Intelligence” in official correspondence, public communications, websites, reports, policy documents, and other non-statutory documents within the executive branch.
This text is not copyrighted and can be reprinted without permission. If any part of the Biennial Report is used in a publication, please provide the Division of the National Interagency Center for the Evaluation of Alternative Test Methods (D-NICEATM) a copy for our records.
Please cite this document as follows:
ICCVAM. 2026. Biennial Progress Report 2024–2025. Research Triangle Park (NC): National Institute of Environmental Health Sciences. Available: https://ntp.niehs.nih.gov/iccvamreport/2025
Send comments or suggestions to D-NICEATM
D-NICEATM Director: Helena Hogberg-Durdock, Ph.D.
D-NICEATM Project Officer/Contracting Officer’s Representative: Chuck Lynch
Report Editors: Andrea Brandt, Anton Kovalsky, Tripp LaPratt, Catherine Sprankle, Catherine Zettel Nalen
The ICCVAM Biennial Report was prepared by D-NICEATM, which is within the NIH Office of Research Innovation, Validation, and Application. Preparation of this report was supported by the Division of Program Coordination, Planning, and Strategic Initiatives within the NIH Office of the Director. Work was conducted under contract GS-35F-393CA-75N94025F00103.